DaraPay Announces Strategic Partnership with Chinese Tech Giant- Alipay
18.11.2019 06:26:00 EET | Business Wire | Press release
DaraPay, the leading mobile E-wallet and payment service providers, today announces its partnership with Alipay, world’s leading payment and lifestyle platform operated by Ant Financial. With this partnership, Chinese tourists can scan and pay with their Alipay app at all DaraPay merchants with more than 3,000 outlets in Phnom Penh, Kandal, Kampong Cham, Siem Reap and Battambang province.
Alipay serves over 1.2 billion users together with its regional partners and is the preferred payment method of Chinese tourists1.
Through this strategic partnership, the two partners are looking to integrate their respective systems with one another and offer the market a flexible, on-demand digital payment solution through which Chinese tourists can conveniently use during their visit to Cambodia.
With the system now in place, Alipay users are no longer required to withdraw cash or perform cross-app money transfer to make payments across the Kingdom. They can simply complete their purchases by scanning the special QR code available at DaraPay-enabled merchant partners.
“We are excited to work with Alipay,” said Mr. Phok Ratha, General Manager of DaraPay. “Through this collaboration, Alipay users can now benefit from the convenience, simplicity, and security of our integrated system and merchant partners while enjoying their vacation in Cambodia.”
With DaraPay's more than 3,000 merchant partners, finding a store or service that accepts this integrated mobile payment should not be a trouble. Whether it is a transaction at a restaurant, café, and supermarket or payment for services such as ride-hailing, hotel, and entertainments, Chinese tourists can truly benefit by choosing the services of DaraPay’s merchant partners. Alipay customers who love shopping for apparel or trying out all types of delicious food can enjoy with the most popular Chinese tourist malls: Sorya Center Point or The Olympia Mall located at the heart of Phnom Penh City.
The future bodes well for the two partners with the number of Chinese tourists visiting the Kingdom continues to grow. Last year, statistically the nation welcomed over 1.7 million Chinese tourists, and the number is expected to rise to 3 million by 2020 and 5 million by 2025.
As the number of Chinese tourists to the Kingdom continues to surge, and following its strategic road map, DaraPay is on track with its collaboration with leading fintech platform Alipay.
Mr. Ratha continued, "The partnership with Alipay is an important step that takes DaraPay to the next level of our business development. We do not only collaborate with local businesses but we are also actively working with international partners as part of our new strategic roadmap to enter a new horizon. In the future, we are looking to collaborate with other international partners to bring better and more innovative services to cater to our customers both the locals and international ones.”
About DaraPay:
DaraPay is a trademark of CANADIA-FULLERTON MOBILE MONEY PLC., a corporation duly established in 2016. DaraPay is a joint venture between Canadia Investment Holding (CIH) of Cambodia and Fullerton Financial Capital (FFC), a subsidiary of Fullerton Financial Holdings (FHH) of Singapore, for the purpose of operating a mobile wallet and payments business in Cambodia. DaraPay’s services include Local Money Remittance, Cash-In / Cash Out, Utilities Bill Payments, Phone Top Up, Bill Payment, E-commerce Payment, Merchant Payment, Loan Repayment, Loan Referral, Payroll service, Mobile Wallet and other financial related products. As of August 2019, DaraPay has more than 4,500 agents nationwide and has more than 3,000 merchants available to accept the payment. Through DaraPay, thousands of people and families in both provinces and urban cities are sending money anywhere, any time at the peace of mind.
Don’t have DaraPay App yet?
Android & iOS users, download now:
https://goo.gl/7tvY1E
DaraPay: Fast, Secure and Everywhere.
About Alipay:
Operated by Ant Financial Services Group, Alipay is the world’s leading payment and lifestyle platform. Launched in 2004, Alipay serves over 1.2 billion users with its local e-wallets partners as of June 2019. Over the years, Alipay has evolved from a digital wallet to a lifestyle enabler. Users can hail a taxi, book a hotel, buy movie tickets, pay utility bills, make appointments with doctors, or purchase wealth management products directly from within the app. In addition to online payments, Alipay is expanding to in-store offline payments both inside and outside of China. Alipay’s in-store payment service covers over 50 markets across the world, and tax reimbursement via Alipay is supported in 35 markets. Alipay currently supports 27 currencies, and works with over 250 overseas financial institutions and payment solution providers to enable cross-border payments for Chinese travelling overseas and overseas customers who purchase products from Chinese e-commerce sites.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191117005080/en/
Contact information
For media inquiry:
Mr. Phok Ratha, General Manager, CANADIA-FULLERTON MOBILE MONEY PLC.
Tel: +855 81 799 888
Email: ratha.phok@darapay.com.kh
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom